Evidence map›Paper›PMID 40281003›Full record

Trial reportScientific reports2025

Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma.

Hideki Goto, Masashi Sawa, Shin-Ichiro Fujiwara, Masaki Ri, Tadao Ishida, Masahiro Takeuchi, Kenji Ishitsuka, Masako Toyosaki, Kazutaka Sunami, Junichi Tsukada and 8 more

Abstract readClinical Trial, Phase IIEquivalence TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hideki GotoDepartment of Hematology, Graduate School of Medicine, Hokkaido University Faculty of Medicine, Sapporo, Japan.
Masashi SawaDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
Shin-Ichiro FujiwaraDivision of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Masaki RiDepartment of Hematology and Oncology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Tadao IshidaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Masahiro TakeuchiDivision of Hematology-Oncology, Chiba Cancer Center, Chiba, Japan.
Kenji IshitsukaDepartment of Hematology and Rheumatology, Kagoshima University, Kagoshima, Japan.
Masako ToyosakiDepartment of Hematology and Oncology, School of Medicine, Tokai University, Isehara, Japan.
Kazutaka SunamiDepartment of Hematology, NHO Okayama Medical Center, Okayama, Japan.
Junichi TsukadaDepartment of Hematology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Takashi SonokiDepartment of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
Aiko ShimogomiKyowa Kirin Co., Ltd, Tokyo, Japan.
Yuki IchihashiKyowa Kirin Co., Ltd, Tokyo, Japan.
Yoshiumi OuchiKyowa Kirin Co., Ltd, Tokyo, Japan.
Toshihiro MiyamotoDepartment of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Masayuki HinoDepartment of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Yoshinobu MaedaDepartment of Hematology and Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Takanori TeshimaDepartment of Hematology, Graduate School of Medicine, Hokkaido University Faculty of Medicine, Sapporo, Japan. teshima@med.hokudai.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This phase 2 study evaluated the impact of pegfilgrastim, a single-dose, long-acting granulocyte colony-stimulating factor, on the steady-state mobilization of hematopoietic stem cells into peripheral blood in patients with multiple myeloma (MM) or malignant lymphoma (ML). Efficacy and safety, along with CD34-positive cell mobilization outcomes were assessed in patients with MM, who were randomly assigned to pegfilgrastim (n = 30) or daily filgrastim (n = 31), and ML (pegfilgrastim only, n = 13) cohorts. In the MM cohort, CD34-positive cell counts ≥ 2 × 10

Indexed as

FilgrastimHematopoietic Stem Cell MobilizationLymphomaMultiple MyelomaPeripheral Blood Stem CellsPolyethylene GlycolsAdultAgedAntigens, CD34BenzylaminesCyclamsFemaleHumansMaleMiddle AgedAntigens, CD34BenzylaminesCyclamsFilgrastimpegfilgrastimplerixaforPolyethylene GlycolsCD34LymphomaMobilizationMultiple myelomaPegfilgrastimPeripheral blood stem cell

Identifiers

PMID40281003
PMCPMC12032086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.